| Literature DB >> 25887596 |
Rachel J Jolley1, Keri Jo Sawka2, Dean W Yergens3, Hude Quan4,5, Nathalie Jetté6,7,8,9, Christopher J Doig10,11,12,13.
Abstract
INTRODUCTION: Administrative health data have been used to study sepsis in large population-based studies. The validity of these study findings depends largely on the quality of the administrative data source and the validity of the case definition used. We systematically reviewed the literature to assess the validity of case definitions of sepsis used with administrative data.Entities:
Mesh:
Year: 2015 PMID: 25887596 PMCID: PMC4403835 DOI: 10.1186/s13054-015-0847-3
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Flow diagram for study screening and article inclusion. ICD, International Classification of Diseases.
Characteristics of studies included and summary of measures reported in validation studies
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cevasco | General surgical | 2003 to 2007 | Population-based, inpatient Veterans Affairs hospital | 112 | ICD-9-CM | Secondary | Medical chart review | – | – | 53% | – |
| General surgical | 2005 to 2007 | Population-based, inpatient community hospital | 164 | ICD-9-CM | Secondary | Medical chart review | – | – | 41% | – | |
| Gedeborg | ICU-specific | 1994 to 1999 | Population-based, inpatient | 4,181 | ICD-9b | Principal, secondary | ICU database | 45.7% | 97.5% | 45.9% | 97.5% |
| ICU-specific | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-10b | Principal, secondary | ICU database | 52.5% | 92.6% | 28.0% | 97.3% | |
| ICU-specific and DI | 1994 to 1999 | Population-based, inpatient | 4,181 | ICD-9b | Principal, secondary | ICU database | 17.2% | 99.4% | 56.1% | 96.3% | |
| ICU-specific and DI | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-10b | Principal, secondary | ICU database | 20.1% | 98.4% | 40.9% | 95.7% | |
| ICU-specific | 1994 to 1999 | Population-based, inpatient | 45 | ICD-9b ICD-10b | Principal, secondary | Sepsis clinical trial patients | 42.2% | 95.5% | 7.4% | 99.5% | |
| ICU-specific | 1994 to 1999 | Inpatient intensivist-coded ICU database | 45 | ICD-9b ICD-10b | Principal, secondary | Sepsis clinical trial patients | 51.5% | 92.6% | 5.6% | 99.6% | |
| ICU-specific | 1994 to 1999 | Population-based, inpatient | 4,181 | ICD-9c | Principal, secondary | ICU database | 43.0% | 98.0% | 49.7% | 97.4% | |
| ICU-specific | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-10c | Principal, secondary | ICU database | 43.0% | 95.6% | – | – | |
| ICU-specific | 1994 to 1999 | Population-based, inpatient | 4,181 | ICD-9b | Principal | ICU database | 31.7% | 99.2% | 63.4% | 97.0% | |
| ICU-specific | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-10b | Principal | ICU database | 21.8% | 97.9% | 36.4% | 95.8% | |
| ICU-specific: CAS | 1994 to 1999 | Population-based, inpatient | 4,181 | ICD-9b | Principal | ICU database | 51.1% | 99.4% | 66.7% | 98.9% | |
| ICU-specific CAS | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-10b | Principal | ICU database | 31.8% | 99.0% | 41.5% | 98.3% | |
| ICU-specific CAP and DI | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-9b | Principal | ICU database | 19.1% | 99.8% | 64.3% | 98.2% | |
| ICU-specific CAS and DI | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-10b | Principal | ICU database | 17.6% | 99.4% | 42.8% | 97.9% | |
| ICU-specific CAS | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-9c | Principal | ICU database | 47.9% | 99.5% | 70.3% | 98.8% | |
| ICU-specific CAS | 1994 to 1999 | Population-based, inpatient | 3,434 | ICD-10c | Principal | ICU database | 27.1% | 99.0% | 39.7% | 98.2% | |
| ICU-specific CAS | 1994 to 1999 | Population-based, inpatient | 45 | ICD-9c ICD-10c | Principal | Sepsis clinical trial patients | 46.9% | 97.4% | 9.9% | 99.7% | |
| ICU-specific CAS | 1994 to 1999 | Inpatient intensivist-coded ICU database | 45 | ICD-9c ICD-10c | Principal | Sepsis clinical trial patients | 31.2% | 98.5% | 10.9% | 99.6% | |
| Grijalva | Rheumatoid arthritis | 1995 to 2004 | Inpatient database | 45 | ICD-9-CM | Principal, secondary | Medical chart review | – | – | 80% | – |
| Ibrahim | General ICU | 2000 to 2006 | Inpatient database | 1,645 | ICD-10-AM | Principal | ICU database | 44.1% | 98.9% | 88.2% | 90.6% |
| General ICU | 2000 to 2006 | Inpatient database | 45 | ICD-10-AM | Principal | ICU database | 16.5% | 99.8% | 93.9% | 86.8% | |
| Iwashyna | General | 2009 to 2010 | Population-based, inpatient | 111 | ICD-9-CM Angus | All | Medical chart review | 50.3% | 96.3% | 70.7% | 91.5% |
| General | 2009 to 2010 | Population-based, inpatient | 111 | ICD-9-CM Explicit | All | Medical chart review | 9.3% | 100% | 100% | 86.0% | |
| General | 2009 to 2010 | Population-based, inpatient | 111 | ICD-9-CM Martin | All | Medical chart review | 16.8% | 99.8% | 97.6% | 87.0% | |
| Lawson | General surgical | 2005 to 2008 | Population-based claims data | 13,410 | ICD-9-CM | All | ACS-NSQIP inpatient surgical database | 46.3% | 94.0% | – | – |
| Madsen | General | 1994 | Population-based, inpatient | 471 | ICD-10, Danish version | Unknown | Bacteraemia database | 5.9% | – | 21.7% | – |
| Ollendorf | Severe sepsis clinical trial patients | No dates given | Population-based, inpatient claims | 122 | ICD-9-CM | All | Severe sepsis clinical trial patients | – | – | 75.4% | – |
| Quan | General surgical | 2007 to 2008 | Population-based, inpatient | 117 | ICD-10 | Secondary | Medical chart review | – | – | 9.8% | – |
| General surgical | 2007 to 2008 | Population-based, inpatient | 34 | ICD-10 | Secondary | Medical chart review | – | – | 12.5% | – | |
| Ramanathan | Surgical patients | 2012 to 2013 | Surgical inpatient | 243 | ICD-9-CM | All | Medical chart review | 82.3% | 78.3% | 91.1% | 62.1% |
| Schneeweiss | General | 2001 to 2004 | Population-based, inpatient | 158 | ICD-9-CM | Principal | Medical chart review | – | – | 91% | – |
| Whittaker | ED admitted inpatients | 2005 to 2009 | Population-based, inpatient | 1,735 | ICD-9 (severe) | All | Medical chart review | 20.5% | – | – | – |
| ED admitted inpatients | 2005 to 2009 | Population-based, inpatient | 1,735 | ICD-9 (severe) | All | Medical chart review | 47.2% (Angus) | – | – | – | |
| ED admitted inpatients | 2005 to 2009 | Population-based, inpatient | 321 | ICD-9 (shock) | All | Medical chart review | 49.5% | – | – | – | |
| ED admitted inpatients | 2005 to 2009 | Population-based, inpatient | 321 | ICD-9 (shock) | All | Medical chart review | 42.4% | – | – | – | |
| ED admitted inpatients | 2005 to 2009 | Population-based, inpatient | 321 | ICD-9 (shock) | All | Medical chart review | 75.1% (Angus) | – | – | – |
aCAS, Community-acquired sepsis (intensive care unit (ICU) admission within 48 hours); DI, Department of Infectious Disease patients; ICD, International Classification of Diseases; AM, Australian Modification; CM, Clinical Modification; ACS-NSQIP, American College of Surgeons National Surgical Quality Improvement Program; ED, Emergency Department; NPV, Negative predictive value; PPV, Positive predictive value; Sn, Sensitivity; Sp, Specificity. bSepsis wide criteria codes. cSepsis narrow criteria codes.
ICD version and ICD codes used in included studies
|
|
|
|
|---|---|---|
| Cevasco | ICD-9-CM | 0380, 0381, 03810, 03811, 03812, 03819, 0382, 0383, 78552, 78559, 9980, 99591, 99592, 03840, 03841, 03842, 03843, 03844, 03849, 0388, 0389 |
| Gedeborg | ICD-9 |
|
| ICD-10 |
| |
| ICD-9 |
| |
| ICD-10 |
| |
| Grijalva | ICD-9-CM | 003.1, 036.2, 785.52, 790.7, 038.x |
| Ibrahim | ICD-10-AM |
|
|
| ||
|
| ||
|
| ||
|
| ||
| Lawson | ICD-9-CM | 038, 78552, 99591, 99592, 9980, 99859, 99931 |
| Madsen | ICD-10, Danish version | A42.7, A41.3, A54.8, P36, P36.5, 36.4, P36.8, P36.2, P36.1, A02.1, A40.0, A40.2, A41.9, A40.8, O08.0, O85.9, A41.1, A41.2, A40.9, O75.3, A41.4, A41.5, P36.0, P36.3, P36.9, A41.0, A40.1, A40.3, A28.2, A41.8 |
| Ollendorf | ICD-9-CM | 038.3, 022.3, 790.7, 038.42, 038.49, 038.40, 038.41, 054.5, 036.2, 038.2, 038.43, 003.1, 038.8, 038.9, 020.2, 038.44, 038.1, 038.0 |
| Schneeweiss | ICD-9-CM |
|
| Quan | ICD-10-CA | A40.0, A40.1, A40.2, A40.3, A40.8, A40.9, A41.0, A41.1, A41.2, A41.3, A41.4, A41.5, A41.8, A41.9, R57.8, T81.1 |
| Iwashyna | ICD-9-CM | Angus positive: |
|
| ||
| OR codes used to identify infection: 001, 002, 003, 004, 005, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018, 021, 022, 023, 024, 025, 026, 027, 030, 031, 032, 033, 034, 035, 036, 037, 038, 039, 040, 041, 090, 091, 092, 093, 094, 095, 096, 097, 098, 100, 101, 102, 103, 104, 110, 111, 112, 114, 115, 116, 117, 118, 320, 322, 324, 325, 420, 421, 451, 461, 462, 463, 464, 465, 481, 482, 485, 486, 491.21, 494, 510, 513, 540, 541, 542, 52.01, 562.03, 562.11, 562.13, 566, 567, 569.5, 569.83, 572.0, 572.1, 575.0, 590, 597, 599.0, 601, 614, 615, 616, 681, 682, 683, 686, 711.0, 730, 790.7, 996.6, 998.5, 999.3; | ||
| AND acute organ dysfunction codes: 785.5, 458, 96.7, 343.3, 293, 348.1, 287.4, 287.5, 286.9, 286.6, 570, 573.4, 584 | ||
| ICD-9-CM |
| |
| ICD-9-CM |
| |
| Ramanathan | ICD-9-CM | 995.91, 995.92, 785.52 |
| Whittaker | ICD-9 | 995.92, 785.52, Angus coding method (see Iwashyna |
aAM, Australian Modification; CA, Canadian edition; CM, Clinical Modification; ICD, International Classification of Diseases.
Quality assessment checklist of reporting criteria for validation studies of health administrative data
|
|
|
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Identify article as study of assessing diagnostic accuracy | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 2. Identify article as study of administrative data | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3. State disease identification & validation as goals of study | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|
| ||||||||||||
| 4. Age | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 5. Disease | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6. Severity | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 7. Location/jurisdiction | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 8. Describe recruitment procedure of validation cohort | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 9. Inclusion criteria | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 10. Exclusion criteria | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| 11. Describe patient sampling (random, consecutive, all, etc.) | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 12. Describe data collection | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 13. Who identified patients and did selection adhere to patient recruitment criteria | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 14. Who collected data | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 15. | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 16. Disease classification | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 17. Split sample (that is, revalidation using a separate cohort) | 0 | 0 | 0 | 0 | 0 | U | 0 | 0 | 0 | 0 | 0 | 0 |
|
| ||||||||||||
| 18. Describe number, training and expertise of persons reading reference standard | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| 19. If more than one person reading reference standard, quote measure of consistency (for example, κ) | 1 | 0 | 1 | N/A | N/A | 0 | 0 | N/A | 0 | 0 | 0 | 0 |
| 20. Blinding of interpreters of reference standard to results of classification by administrative data (for example, chart abstractor blinded to how that chart was coded) | U | 1 | 1 | U | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
|
| ||||||||||||
| 21. Describe methods of calculating diagnostic accuracy | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
|
| ||||||||||||
| 22. Report when study done, start/end dates of enrolment | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 23. Describe number of people who satisfied inclusion/exclusion criteria | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 24. Study flow diagram | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
|
| ||||||||||||
| 25. Report distribution of disease severity | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| 26. Report cross-tabulation of index tests by results of reference standard | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| 27. Report at least four estimates of diagnostic accuracy | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
|
| ||||||||||||
| 28. Sensitivity | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
| 29. Specificity | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| 30. PPV | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 31. NPV | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| 32. Likelihood ratios | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 33. κ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 34. Area under the ROC curve/C-statistic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 35. Accuracy/agreement | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 36. Other (specify) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 37. Report accuracy for subgroups (for example, age, geography) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| 38. If PPV/NPV reported, does the ratio of cases/controls of validation cohort approximate prevalence of condition in the population? | 1 | 1 | N/A | N/A | 1 | N/A | N/A | N/A | N/A | 0 | 0 | N/A |
| 39. Report 95% CI for each diagnostic measure | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
|
| ||||||||||||
| 40. Discuss the applicability of the validation findings | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Total score | 27 | 25 | 27 | 30 | 28 | 24 | 10 | 22 | 28 | 29 | 24 | 26 |
aCI, Confidence interval; N/A, Not applicable; NPV, Negative predictive value; PPV, Positive predictive value; ROC, Receiver operating characteristic. Yes = 1; No = 0; U = Unsure. Adapted from Benchimol et al. [17].